Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 8992 results

  1. Fractures

    All NICE products on fractures. Includes any guidance, advice and quality standards.

    Topic page

  2. Digital health

    All NICE products on digital health. Includes any guidance and quality standards.

    Topic page

  3. Organ and tissue transplantation

    All NICE products on organ and tissue transplantation. Includes any guidance, advice and quality standards.

    Topic page

  4. Pressure ulcers

    All NICE products on pressure ulcers. Includes any guidance, advice and quality standards.

    Topic page

  5. Lower urinary tract symptoms

    All NICE products on lower urinary tract symptoms. Includes any guidance, advice and quality standards.

    Topic page

  6. Lower gastrointestinal lesions

    All NICE products on lower gastrointestinal lesions. Includes any guidance.

    Topic page

  7. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  8. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  9. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  10. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  11. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA867

  12. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 April 2023

    Sections for TA879

  13. Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)

    NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    13 July 2023

    Sections for TA910

  14. Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) (TA899)

    NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 June 2023

    Sections for TA899

  15. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    20 June 2023

    Sections for TA901